Overview
HBOT for post-stroke recovery has been studied in both acute and chronic phases. The 2013 Boussi-Gross RCT demonstrated significant improvements in patients 6 months to 3 years post-stroke using 40 sessions at 2.0 ATA. Mechanisms are hypothesised to include angiogenesis, mitochondrial recovery, and neuroplasticity induction in surviving but dormant penumbra tissue.
Stroke remains a leading cause of adult neurological disability. Standard-of-care treatment includes acute reperfusion therapy (tPA, thrombectomy) within narrow time windows and ongoing rehabilitation. The chronic recovery phase, however, has few interventions beyond rehabilitation — a gap HBOT research has attempted to fill.
The Boussi-Gross et al. 2013 trial (PLoS ONE) is foundational. The study enrolled 74 patients 6 months to 3 years post-stroke and showed significant cognitive and functional gains after 40 sessions at 2.0 ATA, with corresponding improvements on SPECT imaging. The results challenged the then-prevailing view that neurological recovery plateaued at 6 months post-event — a finding now broadly accepted in rehabilitation medicine.
Follow-up research has extended these findings to subgroups (left vs right hemisphere, cognitive vs motor dominant symptoms) and to acute-phase trials. Rosario et al. 2018 and other acute-stroke HBOT trials have produced more mixed results, suggesting that chronic-phase recovery may be the optimal use case rather than hyperacute neuroprotection.
How HBOT Works for This Condition
The post-stroke brain contains a mix of permanently infarcted tissue and surviving-but-dormant tissue in the ischaemic penumbra. HBOT appears to selectively benefit this penumbra tissue. Elevated plasma oxygen reaches cells with marginal blood supply; HIF-1α stabilisation drives angiogenesis and improves microcirculation in previously hypoperfused regions; neuroplasticity signalling (BDNF, growth factors) is upregulated. SPECT and perfusion MRI consistently show increased perfusion in brain areas corresponding to clinical gains. Importantly, infarcted tissue cannot be rescued — HBOT does not regenerate dead neurons.
GRADE Evidence Rating
Efrati 2013 crossover trial supports late-window benefit; replication in independent centres limited. Off-label worldwide.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Limited replication |
| Directness | Direct |
| Precision | Moderate |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 40 sessions at 2.0 ATA, 90 minutes each, 5 days/week |
|---|---|
| Evidence level | Phase 2 RCTs — Moderate evidence |
| FDA status | Not FDA-approved for stroke |
The Boussi-Gross protocol delivers 40 sessions at 2.0 ATA over 8 weeks. Sessions include scheduled air breaks, pre- and post-treatment neurocognitive and functional assessment (NIH Stroke Scale, cognitive batteries, imaging), and interim evaluation. Patients continue standard rehabilitation during the HBOT course.
Evidence Base
Chronic post-stroke HBOT at 2.0 ATA has UHMS Tier 2 evidence. The Boussi-Gross 2013 trial is methodologically strong. Acute-phase trials are more mixed. There is no large multicentre Phase 3 trial yet, though the clinical signal is robust across Efrati Lab publications.
Patient Perspective
Chronic stroke patients considering HBOT typically have persistent cognitive or motor deficits that have not improved with ongoing rehabilitation. Response is partial — HBOT is not a cure but can produce clinically meaningful gains in attention, executive function, and some motor measures. Response varies by stroke location, severity, and time since event. Early stroke (within 6 months) may actually show less benefit than chronic cases where the dormant penumbra tissue has stabilised and is most responsive.
Cautions & Considerations
- Not FDA-approved for stroke; off-label use at cash-pay clinics.
- Acute-phase HBOT (within hours of event) remains investigational.
- Infarcted tissue cannot be regenerated — HBOT addresses the penumbra, not the core infarct.
- Comorbid cardiovascular disease requires cardiac screening before treatment.
- Not a substitute for ongoing physical, occupational, and speech therapy.
Key Research & References
- Boussi-Gross et al. 2013 (PLoS ONE)
- Efrati et al. 2013 (post-stroke neurocognitive)
- Rosario et al. 2018 (acute stroke)
- Hadanny & Efrati 2020 (review)
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
How long after a stroke can HBOT still help?
The Boussi-Gross trial included patients 6 months to 3 years post-stroke; subsequent work has extended this window further. The practical answer: as long as the patient has persistent symptoms thought to involve surviving-but-dormant tissue, HBOT may help. Early acute-phase use is more controversial.
Will HBOT reverse paralysis?
Complete reversal of established paralysis is unlikely. Partial improvement in motor function has been reported, particularly when the deficit relates to the ischaemic penumbra rather than the infarct core. Cognitive gains are generally more consistent than motor gains.
Is HBOT dangerous for stroke patients?
With appropriate screening (cardiac evaluation, blood pressure control, no contraindications), HBOT has an excellent safety profile in post-stroke populations. Patients with uncontrolled hypertension, severe cardiac disease, or recent haemorrhagic events require specific assessment.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.